Podcasts about gvhd

In a cobranded episode between Oncology on the Go, hosted by CancerNetwork®, and the American Society for Transplantation and Cellular Therapy (ASTCT)'s program ASTCT Talks, Mitchell E. Horwitz, MD, highlighted key developments and ongoing initiatives related to allogeneic and cord blood transplantations among patients with different hematologic malignancies. The conversation touched upon the impact of omidubicel-onlv (Omisirge) on patient outcomes, current research on reducing the risk of graft-vs-host disease (GVHD) among transplantation recipients, and strategies for providing effective prophylaxis during treatment, among other topics.

In this episode of ASTCT Talks, host Dr. Corey Cutler, MD, from Dana-Farber Cancer Institute, is joined by Dr. Pooja Khandelwal, MD (Cincinnati Children's Hospital), Dr. Ben Watkins, MD (Tulane University), and Dr. Kenneth Cooke, MD (Johns Hopkins University) for an in-depth discussion on evolving strategies to prevent graft-versus-host disease (GVHD) in pediatric transplant.The conversation explores how leading centers are approaching GVHD prophylaxis across a range of clinical scenarios, with a focus on improving both acute and chronic GVHD outcomes. Experts compare platform-based approaches — including post-transplant cyclophosphamide, calcineurin inhibitor–based regimens, abatacept, and graft manipulation — and discuss how these strategies influence long-term transplant success.Key topics include:Current approaches to reducing acute and chronic GVHD in pediatric patients.Tradeoffs between prevention platforms, including immune reconstitution and infection risk.Emerging data on novel strategies, such as vitamin A and extended co-stimulation blockade.The role of GVHD-free survival as a key endpoint in transplant outcomes.Ongoing challenges and unmet needs in preventing chronic GVHD.While advances in prophylaxis are helping to reduce GVHD incidence, chronic GVHD remains a significant clinical challenge, underscoring the importance of continued innovation across the prevention-treatment continuum.This episode was supported by an educational grant fromIncyte.

Today, Peggy Burkhard talks with Dr. Amar Kelkar of the Dana-Farber Cancer Institute about the medical side of survivorship after bone marrow, stem cell, or CAR-T transplant. The conversation begins with the important shift from the urgent “save my life” phase to the longer “protect my health” phase. Dr. Kelkar explains that this transition often starts around the 100-day mark, though timing varies by transplant center, geographical region and patient needs. A major theme is the need to restart routine care that may have been paused during transplant. Dental care, dermatology, ophthalmology, and primary care all become important again. Dental visits are especially important because oral graft-versus-host disease (GVHD) can cause dry mouth, irritation, cavities, and other problems. Skin checks matter because transplant can increase the risk of skin cancers. Dr. Kelkar stresses annual dermatology visits, sun protection, SPF 50 or higher, protective clothing, and smart decisions about sun exposure. Fatigue is another central topic. Dr. Kelkar describes post-transplant fatigue as different from normal tiredness. It can feel deep, physical, and mental, and it may last for months or even years. He encourages patients to pace themselves, listen to their bodies, and build activity back slowly. Returning to work also needs to be individualized. Some patients work remotely during treatment, while others may need extended disability or a gradual return. The episode also covers immune recovery and repeat vaccinations. Dr. Kelkar explains that after transplant, the immune system has been reset, and many childhood vaccines need to be repeated. Most programs begin revaccination around six, nine, or 12 months, depending on immune suppression and other factors. He reassures listeners that many patients have fewer vaccine symptoms early on because their immune systems are still rebuilding. Dr. Kelkar also reviews long-term screening and prevention. Survivors need routine cancer screenings, including mammograms, colonoscopies, lung cancer screening when appropriate, skin exams, and monitoring for thyroid or other changes. Metabolic health is also important. Steroids can affect blood sugar, transplant can change body composition, and quick weight loss often includes muscle loss. Nutrition support and exercise programs can help, and Peggy notes that Blood Cancer United offers nutrition services for patients and caregivers. Blood Cancer United's nutrition program provides free one-on-one consultations with oncology dietitians by phone or email. Bone health, hormone changes, sexual health, and early aging are also discussed. Dr. Kelkar explains that steroids, menopause, testosterone changes, vitamin D deficiency, and time indoors can affect bones. Many centers use DEXA scans and vitamin D supplementation. He also encourages patients to bring up sexual health concerns, including menopause symptoms, low testosterone, pain with intercourse, ulcers, or fear about resuming intimacy. The episode closes with practical advice for everyday life. Food restrictions often loosen around 100 days, but patients should reintroduce foods slowly and carefully. Raw foods, alcohol, tobacco, and inhaled smoke should generally be avoided, especially during the first year. Dr. Kelkar also emphasizes mental health support, counseling, and honest conversations with the medical team. Survivorship is a bumpy road, but the goal is to help patients regain control and thrive. Blood Cancer United Nutrition Offerings: https://bloodcancerunited.org/blood-cancer-care/adults/food-nutrition Thanks to this season's sponsors, Incyte and Sanofi. (00:00) Intro (01:16) Moving from acute treatment to survivorship (02:17) Dental, dermatology, ophthalmology, and routine care (05:45) Fatigue after transplant versus normal tiredness (08:35) Pacing yourself and avoiding setbacks (10:26) Returning to work after transplant (12:24) Resetting the immune system and repeat vaccinations (16:07) Secondary malignancy prevention and cancer screenings (18:59) Sun protection and skin cancer prevention (20:23) Metabolic health, blood sugar, and weight management (23:58) Bone health, vitamin D, DEXA scans, and early aging (29:32) Sexual health and hormonal changes (32:43) Everyday living after transplant (36:07) Psychological and cognitive hurdles in survivorship (38:16) Pulmonary function tests and liver monitoring (40:42) Closing thoughts National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/Check out our valued nbmtLINK resource books, some for sale, some free as downloadable, https://www.nbmtlink.org/shop/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.This content is provided for informational purposes only and is not intended to substitute for professional medical advice, diagnosis, or treatment. It is crucial to consult directly with a qualified healthcare professional regarding any medical conditions, treatment options, or other health concerns.The views and opinions expressed by the speakers are their own and do not necessarily reflect the official policy or position of the nbmtLINK. Unless otherwise stated in an official policy, the nbmtLINK does not endorse any specific treatments, products, or services mentioned by the speakers. Reliance on any information provided is solely at your own risk.The Marrow Masters Podcast is produced by JAG Podcast Productions: https://jagpodcastproductions.com/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Today, Peggy talks with Daniel Gaylor, LCSW, OSW-C, ACHP-SW, and a social work supervisor at Moffitt Cancer Center, about what happens after patients and caregivers get through the intense treatment period and begin asking, “Now what?” Daniel explains that recovery does not mean life snaps back to normal. Survivorship brings fear, relief, hope, uncertainty, and exhaustion all at once. Those reactions are normal, and they deserve to be named. Daniel explains why post-traumatic stress disorder (PTSD) can show up after transplant. A transplant is not a routine treatment. It can involve long hospital stays, isolation, major physical side effects, and real fears about survival. When patients return for follow up visits, they may be brought back emotionally to those difficult hospital days. This can make survivorship feel complicated, even when the transplant was successful. Another key theme is slowly letting go. Patients may feel afraid to go out, socialize, eat in a restaurant, drive, or return to activities they once enjoyed. Daniel encourages survivors to start small and to be fair to the situation. It is easy to imagine the worst case. But it also helps to keep yourself honest - say out loud what could happen if things go well. The episode also addresses the “strain of worry.” Daniel describes signs of anxiety and depression, including sleep problems, racing thoughts, trouble concentrating, irritability, sadness, appetite changes, and not wanting to do things that usually bring joy. He reminds listeners that difficult days do not mean failure. Survivors should be able to say, “Today is not my best day,” and ask for help. Peggy and Daniel also talk about toxic positivity. While loved ones often mean well, phrases like “you're lucky to be alive” can minimize a survivor's fear or pain. Daniel encourages honest communication. Patients can thank loved ones for their support while also explaining what would help more. Social connection is another major part of healing. Daniel urges survivors and caregivers to increase connection and reduce isolation. A quick text, a short call, a support group, or a shared conversation can make a real difference. Peggy highlights programs where survivors can meet others who understand graft versus host disease (GVHD) and transplant recovery. Daniel closes with the idea of building a “tool belt.” Each person needs practical coping tools, whether that is a friend, music, journaling, counseling, mindfulness, a book, or a favorite place to reset. Caregivers need their own tool belts too. Transplant affects the whole support system, and survivorship works best when people communicate, ask for help, and remember they are not meant to do this alone. Links: Elephants and Tea: https://elephantsandtea.org/ BMT InfoNet: https://bmtinfonet.org/ Blood Cancer United: https://bloodcancerunited.org/ Thanks to this season's sponsors, Incyte and Sanofi. (00:00) Intro (01:01) Normalizing emotional reactions during recovery (04:22) PTSD after transplant and why it matters (08:59) Slowly letting go after transplant (13:12) Facing the worst case and choosing to move forward (13:53) The strain of worry and mental health red flags (19:31) Toxic positivity and the power of validation (20:26) How to talk with loved ones who are trying to help (22:39) Social health, connection, and friendship (26:43) Support groups, GVHD, and feeling understood (28:07) Building a survivorship "tool belt" (33:08) Why transplant never fully “stops” (36:39) A patient story about resilience and asking for help National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/Check out our valued nbmtLINK resource books, some for sale, some free as downloadable, https://www.nbmtlink.org/shop/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.This content is provided for informational purposes only and is not intended to substitute for professional medical advice, diagnosis, or treatment. It is crucial to consult directly with a qualified healthcare professional regarding any medical conditions, treatment options, or other health concerns.The views and opinions expressed by the speakers are their own and do not necessarily reflect the official policy or position of the nbmtLINK. Unless otherwise stated in an official policy, the nbmtLINK does not endorse any specific treatments, products, or services mentioned by the speakers. Reliance on any information provided is solely at your own risk.The Marrow Masters Podcast is produced by JAG Podcast Productions: https://jagpodcastproductions.com/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of Marrow Masters, we talk with Adam Claxton, a British acute myeloid leukemia (AML) survivor who was diagnosed in 2024 and received a transplant in December 2024. He shares what early survivorship really feels like, especially the part no one prepares you for. Once treatment slows down, there is a gap between being a patient and figuring out who you are in the world again. Adam explains that around the 100 day mark, he felt dropped out of the system and forced to ask where he fit, what had changed, and who he was becoming after transplant. We also discuss graft versus host disease (GVHD) and how Adam reframes it. He calls it the price he pays for leukemic protection. That shift in perspective helps him see chronic GVHD not only as a complication, but also as evidence that the donor cells are doing their job. He is honest that it can be difficult physically and mentally, but he chooses to view it as part of survival and a sign that his body is being protected. A major focus of the conversation is mindset. Adam talks about mindset as something we have to work on daily, just like updating a device. He believes our thoughts shape how we feel, behave, and respond, and that mental habits matter just as much as physical recovery. He also opens up about relapse, calling it an even harder battle than the initial diagnosis. What helps him move through it is staying connected to his reasons for going on, including his family, his purpose, and his desire to help more people with his voice and experience. The episode also looks at faith over fear. Adam says both fear and faith still take you through the day, so he would rather choose the path that gives him hope. That same thinking connects to what he calls the reset after transplant. He realized he could not simply return to the same life, work, and identity he had before cancer. His priorities had changed, and so had his sense of purpose. Instead of trying to recover the old version of himself, he began building a new one. On a practical level, Adam shares advice about routines, mindfulness, exercise, social media boundaries, and finding joy again in simple things. One of his best suggestions is to go back to the things you loved doing around age 12, because those activities often reconnect you with peace, play, and presence. He also speaks warmly about the importance of support, especially from his wife and children, while reminding us that caregivers carry their own emotional burden too. By the end, Adam leaves listeners with a clear message. Survivors need to be kinder to themselves, own their stories, and start sharing what they have learned. His closing affirmation says it best: we can, we will, we must. More: Adam's Book, Daddy's Magic Blood, on Amazon: https://www.amazon.com/Daddys-Magic-Blood-story-healing/dp/B0GLGXHGW6 Thanks to this season's sponsors, Incyte and Sanofi. (00:00) Intro (01:52) The gap after treatment and early survivorship (03:52) Why survivorship can feel harder than treatment (07:24) Mindset and daily mental conditioning (10:23) Handling relapse and staying connected to purpose (13:20) Faith over fear (15:31) The post transplant identity reset (23:19) Social media, support, and emotional boundaries (26:50) The role of family and caregiver support (29:12) What survivors need more of (32:28) Final affirmation: We can, we will, we must National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/Check out our valued nbmtLINK resource books, some for sale, some free as downloadable, https://www.nbmtlink.org/shop/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.This content is provided for informational purposes only and is not intended to substitute for professional medical advice, diagnosis, or treatment. It is crucial to consult directly with a qualified healthcare professional regarding any medical conditions, treatment options, or other health concerns.The views and opinions expressed by the speakers are their own and do not necessarily reflect the official policy or position of the nbmtLINK. Unless otherwise stated in an official policy, the nbmtLINK does not endorse any specific treatments, products, or services mentioned by the speakers. Reliance on any information provided is solely at your own risk.The Marrow Masters Podcast is produced by JAG Podcast Productions: https://jagpodcastproductions.com/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of Marrow Masters, Peggy Burkhard talks with caregiver Ashlee Cramer about what caregiving really looks like during cancer, bone marrow transplant, and survivorship. Ashlee shares the story of her son Michael, who was diagnosed in 2020 with hepatosplenic T-cell lymphoma. Their family had already lived through cancer once before, when Ashlee's husband Patrice was diagnosed with large B-cell lymphoma in 2014 and later died at home in hospice, surrounded by his family. Ashlee explains that caregiving is often misunderstood. Caregivers are not saints who always feel strong, positive, or ready. Many are scared, exhausted, grieving, and trying to manage jobs, children, finances, appointments, medications, and the emotional weight of watching someone they love suffer. She says caregivers often feel pressure to do everything alone, but that pressure can lead to burnout and isolation. The conversation focuses on the reality that caregiving is not always temporary or predictable. For Michael, treatment moved quickly from diagnosis to hospitalization to transplant. He received a stem cell transplant from an anonymous donor, went into remission, and then developed serious complications, including engraftment syndrome, acute graft versus host disease (GVHD) , and chronic GVHD. Ashlee says Michael is a miracle, and while GVHD remains part of his life, the key word is living. Ashlee also talks about mental health for caregivers. She names anxiety, depression, post-traumatic stress disorder (PTSD), burnout, and loneliness as common experiences. She points out that many cancer centers offer support for patients, but caregivers often have to search for help on their own. Support groups, virtual programs, and caregiver resources can make a major difference because connection helps people feel less alone. A central message of the episode is that caregivers need care too. Ashlee encourages caregivers to take small pockets of peace when they cannot take a full day away. A shower, a breathwork practice, a walk outside, a cup of coffee, or a short hug from another caregiver can help. She also reminds caregivers to accept help. A meal train, a friend waiting in the hospital lobby, or someone offering a few minutes of support can ease the load. The episode ends with hope. Ashlee talks about post-traumatic growth, or PTG, and the idea that people do not have to bounce back to who they were before trauma. They can bounce forward. Michael and Ashlee continue to advocate, share their story through their podcast Michael and Mom Talk Cancer, and remind other caregivers that they are not alone. Thanks to this season's sponsors, Incyte and Sanofi. (00:00 Intro (04:05) Misconceptions about caregiving and why caregivers are not saints (05:30) Why caregivers should not be expected to do everything alone (07:00) The pressure to “stay strong” and how it can isolate caregivers (09:49) The reality of caregiving and how much it affects mental health (12:03) Work, family, sacrifice, and the myth of balance (16:40) Caregiver anxiety, depression, PTSD, burnout, and the need for support (20:40) Finding small “pockets of peace” when a full break is impossible (23:10) What Ashlee wishes she knew earlier about speaking up and asking questions (24:59) Why accepting help matters and how a meal train supported her family (34:09) Post-traumatic growth and the idea of bouncing forward instead of bouncing back National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/Check out our valued nbmtLINK resource books, some for sale, some free as downloadable, https://www.nbmtlink.org/shop/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.This content is provided for informational purposes only and is not intended to substitute for professional medical advice, diagnosis, or treatment. It is crucial to consult directly with a qualified healthcare professional regarding any medical conditions, treatment options, or other health concerns.The views and opinions expressed by the speakers are their own and do not necessarily reflect the official policy or position of the nbmtLINK. Unless otherwise stated in an official policy, the nbmtLINK does not endorse any specific treatments, products, or services mentioned by the speakers. Reliance on any information provided is solely at your own risk.The Marrow Masters Podcast is produced by JAG Podcast Productions: https://jagpodcastproductions.com/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In a cobranded episode between Oncology on the Go, hosted by CancerNetwork®, and the American Society for Transplantation and Cellular Therapy (ASTCT)'s program ASTCT Talks, Mitchell E. Horwitz, MD, highlighted key developments and ongoing initiatives related to allogeneic and cord blood transplantations among patients with different hematologic malignancies. The conversation touched upon the impact of omidubicel-onlv (Omisirge) on patient outcomes, current research on reducing the risk of graft-versus-host disease (GVHD) among transplantation recipients, and strategies for providing effective prophylaxis during treatment, among other topics. According to Horwitz, omidubicel has served as an “important graft source” for pediatric patients while improving cord blood transplantation for adults since its FDA approval in April 2023 for patients 12 years and older with hematologic malignancies. He also spoke to the importance of the FDA's approval of the agent in December 2025 for patients with severe aplastic anemia and no compatible donors following reduced intensity conditioning. Regarding those with severe aplastic anemia, he noted that omidubicel may considerably improve the feasibility of cord blood as a graft source for transplantation.Beyond these approvals, Horwitz described ongoing work dedicated to reducing the risk of GVHD following cord blood-derived transplantation, citing a pilot study that he and colleagues are conducting to determine the feasibility of adding a co-stimulatory blocking monoclonal antibody to help further limit this risk. Additionally, he emphasized surveilling for viruses like Epstein-Barr virus, HHV-6, and cytomegalovirus to mitigate the risks of delayed immune recovery following transplantation.“It's important to have all these [graft sources], whether it be cord blood, mismatched family members, mismatched unrelated donors, and matched siblings…to be made available [and] studied extensively,” Horwitz concluded. “We need to find what the best niche would be for each of these graft sources and make sure that [they] are utilized at the various institutions. The nuances, such as infection prophylaxis or infection monitoring, [should become] familiar to the transplant centers. By doing that, we can continue this trend of having a graft source for everyone and improving outcomes.”Horwitz is a professor of Medicine, Hematologic Malignancies and Cellular Therapy at Duke University School of Medicine and cellular therapy and stem cell specialist at Duke Cancer Institute.References FDA approves cell therapy for patients with blood cancers to reduce risk of infection following stem cell transplantation. News release. FDA. April 17, 2023. Accessed May 20, 2026. bit.ly/3UEO3kp FDA approves first cellular therapy to treat patients with severe aplastic anemia. News release. FDA. December 8, 2025. Accessed May 20, 2026. https://tinyurl.com/yuu377yt

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/ZWS865. CME/AAPA credit will be available until April 23, 2027.An Immune Reset for AlloHCT Recipients: Updates on Engineered Cell Therapy for Improving Transplant Outcomes and Reducing GVHD In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Orca Bio.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/ZWS865. CME/AAPA credit will be available until April 23, 2027.An Immune Reset for AlloHCT Recipients: Updates on Engineered Cell Therapy for Improving Transplant Outcomes and Reducing GVHD In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Orca Bio.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/ZWS865. CME/AAPA credit will be available until April 23, 2027.An Immune Reset for AlloHCT Recipients: Updates on Engineered Cell Therapy for Improving Transplant Outcomes and Reducing GVHD In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Orca Bio.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/ZWS865. CME/AAPA credit will be available until April 23, 2027.An Immune Reset for AlloHCT Recipients: Updates on Engineered Cell Therapy for Improving Transplant Outcomes and Reducing GVHD In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Orca Bio.Disclosure information is available at the beginning of the video presentation.

In this podcast, experts Carrie L. Kitko, MD; Miguel-Angel Perales, MD; and Amandeep Salhotra, MD, discuss GVHD prophylaxis strategies and therapies to address treatment-naive and steroid-refractory chronic GVHD.

Learn how new approaches in allogeneic transplants, from PTCy to innovative regimens, are helping reduce GVHD and improve patient outcomes with special guest Sagar S. Patel, MD of University of Utah Health.

Cytomegalovirus (CMV) infection is one of the most significant infectious complications after hematopoietic cell transplant (HCT). In this podcast, featuring curated audio from a live satellite symposium, experts Roy F. Chemaly, MD, MPH, FIDSA, FACP, FESCMID and Marcus Pereira, MD, MPH, FAST, discuss the burden of CMV in HCT recipients and explore strategies effectively identify and monitor high-risk patients. Topics include: Epidemiology of CMV among HCT recipients Direct and indirect effects of CMV after HCT Dynamics of risk factors for CMV infection  Strategies for prevention of CMV infection To view the full educational program and download the accompanying slides, visit our website:https://bit.ly/4lfrDTT Presenters: Roy F. Chemaly, MD, MPH, FIDSA, FACP, FESCMID Professor and Chair G.P. Bodey, Sr. Distinguished Professorship in Infectious Diseases President, The International Immunocompromised Host Society (ICHS) Director, Clinical Virology Research Department of ID/IC/EH UT MD Anderson Cancer Center Houston, Texas Marcus Pereira, MD, MPH, FAST Associate Professor of Medicine Director of Clinical Services, Division of Infectious Diseases Medical Director, Transplant Infectious Disease Program Columbia University Irving Medical Center New York, New York Get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Cytomegalovirus (CMV) infection is one of the most significant infectious complications after hematopoietic cell transplant (HCT), but there have been major advances in CMV management to date. In this podcast, featuring curated audio from a live satellite symposium, experts Roy F. Chemaly, MD, MPH, FIDSA, FACP, FESCMID, and Marcus Pereira, MD, MPH, FAST, discuss considerations for CMV treatment in HCT recipients and examine treatment options for refractory/resistant CMV. Topics include: Considerations for CMV management in HCT recipients New definitions of refractory and resistant CMV  Risk factors for refractory and resistant CMV infections Identifying drug-resistant CMV  Treatment options for refractory/resistant CMV To view the full educational program and download the accompanying slides, visit our website:https://bit.ly/4lfrDTT Presenters: Roy F. Chemaly, MD, MPH, FIDSA, FACP, FESCMID Professor and Chair G.P. Bodey, Sr. Distinguished Professorship in Infectious Diseases President, The International Immunocompromised Host Society (ICHS) Director, Clinical Virology Research Department of ID/IC/EH UT MD Anderson Cancer Center Houston, Texas Marcus Pereira, MD, MPH, FAST Associate Professor of Medicine Director of Clinical Services, Division of Infectious Diseases Medical Director, Transplant Infectious Disease Program Columbia University Irving Medical Center New York, New York Get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

A transplant saves a life… but can also make the body attack itself. That's what Graft Versus Host Disease (GVHD) does, and why nurses need to catch it early. You may have never seen it before, but this episode will tell you what it looks like at the bedside and the early clues you can't afford to miss.Through a real patient case, Anthony, RN explains why GVHD is easy to overlook, how to think through common differentials, and what matters most when it comes to helping patients stabilize and recover.Topics discussed in this episode:CCOT's rapid response modelThe patient's condition weeks after allogenic transplantAnthony's assessment and what raised red flagsWhy early symptoms can get misread or minimizedHow Graft Versus Host Disease developsWhy emotional support is crucial to recoveryAcute vs. chronic Graft Versus Host DiseaseImportant early clues of Graft Versus Host DiseasePriority interventions for Graft Versus Host DiseaseHow Anthony's app can help bedside nursesYou can connect with Anthony or learn more about his apps here:https://thehumblenurse.com/Mentioned in this episode:CONNECT

Interview with Emily Baumrin, MD, MSCE, author of Discordance in Treatment Response Assessment Between Clinicians and Patients With Skin Chronic Graft-vs-Host Disease. Hosted by Adewole S. Adamson, MD. Related Content: Discordance in Treatment Response Assessment Between Clinicians and Patients With Skin Chronic Graft-vs-Host Disease

Interview with Emily Baumrin, MD, MSCE, author of Discordance in Treatment Response Assessment Between Clinicians and Patients With Skin Chronic Graft-vs-Host Disease. Hosted by Adewole S. Adamson, MD. Related Content: Discordance in Treatment Response Assessment Between Clinicians and Patients With Skin Chronic Graft-vs-Host Disease

In this episode, we sit down with Dr. Joseph Pidala from the Moffitt Cancer Center to discuss chronic graft-versus-host disease (GVHD), a complex condition affecting many stem cell transplant survivors. We focus on the latest prevention strategies, treatment innovations, and the critical role that clinical trials continue to play in advancing care.We begin with promising news around prevention. Dr. Pidala shares data from the BMT CTN 1703 trial, which compared conventional GVHD prevention to a newer approach using post-transplant cyclophosphamide (PTCy). This newer strategy significantly reduced the incidence of both acute and chronic GVHD, signaling a major step forward in preventing this debilitating condition.Despite advancements, many patients still experience chronic GVHD, which drives the need for new treatments. We explore several groundbreaking clinical trials that are rethinking traditional steroid-heavy treatment protocols. One study is testing Rezurock (Belumosudil) as a preemptive treatment during early symptoms, while another is investigating whether Jakafi (Ruxolitinib) can be used as a first-line treatment to reduce steroid reliance. These trials challenge old norms and aim to improve long-term outcomes.We also take a look at the four FDA-approved therapies currently available for steroid-refractory chronic GVHD: Ibrutinib, Jakafi, Rezurock, and the most recent addition, Axatilimab (Niktimvo). These drugs, each with different mechanisms and side effects, give patients and clinicians more flexibility than ever before. We touch on other widely used therapies like ECP (photopheresis), which, while not FDA-approved, remain an important part of care.Patient involvement is a key theme throughout. Dr. Pidala emphasizes that progress would be impossible without those who enroll in clinical trials, sharing inspiring examples of patients who benefited from early access to now-approved drugs. He encourages patients to advocate for themselves and speak up about symptoms, improvements, or quality of life changes. Patient-reported outcomes are becoming standard in trials, offering critical insight into treatment success from the patient's perspective.Dr. Pidala also highlights the importance of addressing GVHD holistically. Beyond core treatments, supportive care—including help with dry eyes, itching, joint mobility, pain, and mental health—is crucial to improving day-to-day life. He stresses that long-term recovery is possible and shares a moving story of a young woman with severe GVHD who, through persistent treatment, regained functionality and returned to a fulfilling life.We close with advice for patients: be proactive, informed, and open to trial participation. And when seeking information on trials, always start by asking your clinical team—they'll know what's available and suitable for your specific situation. Above all, Dr. Pidala leaves us with a message of hope—there's real progress being made, and the future looks brighter than ever.Thanks to our Season 19 sponsors, Incyte and Sanofi.https://incyte.com/https://www.sanofi.com/en00:40 – Introduction to Dr. Joseph Pidala01:21 – New GVHD Prevention Approaches02:44 – Why Clinical Trials Matter03:22 – Challenging Steroid-Based Treatment Norms06:14 – Timeline for New Treatment Results07:02 – FDA-Approved Drugs for Chronic GVHD09:09 – Individualized Treatment Approaches10:69 – The Role of Patient-Reported Outcomes13:44 – Symptom Management and Supportive Care15:20 – Addressing Mental Health in GVHD17:30 – Inspirational Patient Story21:12 – Advice for GVHD Patients23:02 – How to Find Clinical Trials25:06 – Final Thoughts and Message of Hope National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.To participate in the GVHD Mosaic, click here: https://amp.livemosaics.com/gvhd Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, we talk with caregiver Sylvia Chunn of Nashville, who shares her journey alongside her husband David through his diagnosis of AML, a stem cell transplant, and the ongoing challenges of GVHD. Sylvia walks us through their intense timeline, from David's emergency diagnosis in January 2024 to his transplant in July and their extended stay in Atlanta, away from home and their teenage children, until February 2025. Her husband's transplant was successful in its purpose, but complications like heart failure and GVHD turned their lives upside down.We explore the caregiving experience through Sylvia's eyes, especially navigating chronic GVHD symptoms that affect David's gut, eyes, mouth, joints, and skin. She explains how their lives are now filled with medical appointments, medications, and managing side effects from treatment. Sylvia describes her role as a blend of cheerleader and drill sergeant, ensuring medications are taken and appointments kept, while also offering emotional support.Sylvia emphasizes the importance of self-care during the process. With limited financial flexibility, she found peace in simple things like reading through a Facebook book club, daily personal devotions, and leaning on her faith. Exercise helped at times, although maintaining consistency was difficult. She openly shares that she sought mental health support, including therapy and medication, to deal with stress, guilt, and isolation.The conversation turns to how this journey has affected intimacy and family dynamics. Sylvia candidly reflects on how medical realities changed their physical relationship but ultimately brought them emotionally closer. Time spent together—reading, reminiscing, and watching shows—became a new form of connection. They rediscovered old routines from their early marriage and built a stronger bond through shared trials.Sylvia also shares how their children, especially their youngest teenage twins and their adult daughter in medical school, responded to the crisis. She notes how her kids matured emotionally, became more empathetic, and stepped up in unexpected ways.We close with Sylvia offering heartfelt advice to other caregivers: keep showing up, stay grateful, and never forget the power of hope. She reminds us that while this journey is incredibly difficult, it's also filled with unexpected moments of closeness, resilience, and love.Thanks to our Season 19 sponsors, Incyte and Sanofi.https://incyte.com/https://www.sanofi.com/en00:40 - Introduction to Sylvia Chunn01:15 - David's AML Diagnosis and Transplant Decision02:10 - Living Away from Home for Treatment03:40 - Navigating Chronic GVHD05:30 - Caregiver Role and Daily Routine06:40 - Self-Care and Coping Strategies08:20 - Mental Health Support for Caregivers09:40 - Isolation and Infection Risks11:55 - Impact on Intimacy and Marriage16:20 - Parenting Through the Crisis18:40 - Reflections on Family Growth20:40 - Final Thoughts and Advice to Caregivers National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.To participate in the GVHD Mosaic, click here: https://amp.livemosaics.com/gvhd Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, we speak with Synary Be, a resilient survivor of acute myeloid leukemia (AML), who shares her powerful journey of enduring three bone marrow transplants over eight years. Diagnosed suddenly in March 2017, Synary's story begins with a high fever that led to a shocking diagnosis: 93% leukemia. From that point on, her life transformed into a series of hospital stays, treatments, and moments that tested her strength and spirit.We learn how her first transplant involved two umbilical cord donors, one from the U.S. and another from Singapore. When that failed to graft, her younger brother flew from Australia to donate for her second transplant—a 50% match. After two years in remission, she relapsed again and required a third transplant, this time from her older brother, right in the midst of the COVID-19 pandemic. With travel restrictions in place, the donor cells had to be processed remotely and shipped to Stanford, showcasing the remarkable role of medical technology in saving lives.Despite being given only a 50% chance of survival for her third transplant, Synary put her trust in her doctors. Though she relapsed again, she now maintains remission through chemo pills. With no long-term data available for this new medication, she continues treatment cautiously and with optimism, trusting in the advancement of medicine.Synary spends some time opening up about the chronic graft-versus-host disease (GVHD) that followed her transplants. She explains its impact on her lungs, eyes, mouth, nails, and skin, detailing both the physical symptoms and the treatments that have helped her reclaim daily life. From scleral lenses to serum tears, to pulmonary rehab and steroid creams, she educates us on the challenges and management of GVHD.Beyond the physical toll, Synary discusses the mental health struggles tied to long-term illness—particularly anxiety from repeated hospitalizations. She emphasizes the importance of therapy, meditation, support groups, and the courage to seek help. Her words serve as a reminder that managing chronic illness includes caring for both mind and body.Synary's story wouldn't be complete without acknowledging her support system. Her husband, who acted as her full-time caregiver through 300 cumulative days of hospitalization, and her three children, endured major sacrifices. Friends and community support filled in the gaps, underscoring that no one should navigate transplant recovery alone.Even in the face of isolation, fatigue, and anxiety, Synary finds joy in simple pleasures: watching Christmas movies, going for walks, and spending time with family. Her message is clear—life is still good. And GVHD, while challenging, cannot take away her joy.Calm App — https://www.calm.comThanks to our Season 19 sponsors, Incyte and Sanofi.https://incyte.com/https://www.sanofi.com/en00:40 - Introduction to Synary Be01:20 - AML Diagnosis and First Transplant03:10 - Transplants and Donor Challenges04:06 - Relapses and Chemo Maintenance06:44 - Living with GVHD12:15 - GVHD Symptoms and Treatments13:40 - Support System and Caregiving15:34 - Isolation After Transplants16:38 - Mental Health & Anxiety19:03 - Coping and Finding Joy20:36 - Final Thoughts and Message of Hope National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.To participate in the GVHD Mosaic, click here: https://amp.livemosaics.com/gvhd Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, we sit down with Sue Stewart, a 36-year survivor of acute myeloid leukemia (AML) and the founder of BMT InfoNet. Sue walks us through her transplant journey, beginning with a difficult diagnosis in the late 1980s and the grueling induction chemotherapy that followed. With limited treatment options, she opted for an autologous bone marrow transplant—a relatively new and uncertain procedure at the time. Despite the intense side effects, including confusion and delusions, Sue recovered and slowly rebuilt her life. Her story is one of strength and long-term resilience, shaped by medical challenges and a determination to help others facing similar paths.After surviving her transplant, Sue felt driven to understand her experience and quickly saw the gap in patient-centered information. A high-profile court case involving bone marrow donation misinformation pushed her to act. In response, she started a small newsletter to provide reliable, understandable transplant information. What began with 700 names (pre-Internet) grew rapidly and became BMT InfoNet, an organization that now supports over 20,000 people weekly with resources, educational content, and peer support.We explore how GVHD care has transformed over the decades. Sue outlines progress in diagnostics, treatment options, and the move away from long-term steroid reliance. Her organization has helped shift the focus beyond survival to long-term quality of life, leading to the creation of survivorship clinics and a deeper understanding of transplant-related complications.Sue introduces us to BMT InfoNet's key programs, including Caring Connections, which matches patients and caregivers with peers based on similar experiences. We also learn about their online, professionally moderated support groups, offered to different patient communities. These groups have been instrumental in helping individuals process their experiences and stay connected.The organization's educational materials and annual survivorship symposium continue to empower patients to become active members of their care teams. Sue emphasizes the importance of recognizing symptoms early, understanding treatment options, and advocating for proper care—especially for GVHD, which many local doctors may not fully understand.Finally, Sue shares the story of how one patient's experience with ocular GVHD and scleral lenses led to a wider medical breakthrough. It's a powerful reminder of how patients can change the landscape of care by sharing their stories. BMT InfoNet's mission remains clear: provide support, share knowledge, and give voice to those on the transplant journey.BMT InfoNet: https://www.bmtinfonet.orgContact Email: help@bmtinfonet.orgThanks to our Season 19 sponsors, Incyte and Sanofi.https://incyte.com/https://www.sanofi.com/en00:40 - Introduction to Sue Stewart01:15 - Sue's AML Diagnosis and Transplant Story06:33 - Founding BMT InfoNet10:05 - Life Before the Internet: Lack of Resources12:43 - Progress in GVHD Treatment15:25 - Peer Support Through Caring Connections17:16 - Online Moderated Support Groups18:58 - Educational Resources on GVHD21:57 - GVHD Specialist Directory24:05 - Annual Survivorship Symposium26:17 - Financial Assistance for Patients27:39 - GVHD Wall of Hope and National GVHD Day30:01 - Final Story: How Patient Experience Changed GVHD Care National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.To participate in the GVHD Mosaic, click here: https://amp.livemosaics.com/gvhd Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, we speak with Rebecca Heimsoth, a young mother and survivor of myelodysplastic syndrome who underwent a bone marrow transplant in April 2022. Diagnosed shortly after turning 33, Rebecca shares her deeply personal journey of navigating transplant recovery, chronic graft-versus-host disease (GVHD), and parenting two small children. Her story is one of resilience, support, and a constant fight to reclaim her life after cancer.We begin by learning how Rebecca's transplant process unfolded with the support of her family. Her mother stepped in as her full-time caregiver while she temporarily relocated over an hour away from home for five months, separated from her children. Her youngest sister was a full match donor, which initially reduced concern for GVHD—until lung GVHD symptoms appeared five months post-transplant. This diagnosis triggered new fears, especially around survival, and marked the beginning of her chronic GVHD journey, which later expanded to include fascia involvement. Rebecca explains the physical and emotional toll—early menopause, chronic fatigue, cognitive effects, and mobility challenges.We discuss how she manages flare-ups with physical therapy, walking, stretching, and even cupping. Despite the physical setbacks, Rebecca remains actively involved with her family, thanks to a flexible job, long-term disability support, and a strong support system. Her husband takes on parenting duties when her health dips, and her kids have learned small routines to help protect her from illness, such as wearing masks and showering after school. These steps, while difficult, have helped them all cope as a unit.Rebecca also opens up about the mental health side of survivorship—dealing with PTSD, depression, and a sense of loss over her former self. She credits her psychologist, psychiatrist, and peer support groups as vital tools for managing the psychological weight. Online and in-person GVHD groups have connected her to other young adults navigating similar terrain, helping her feel less alone.Despite not returning to her full-time career, Rebecca is finding meaning in her part-time work and family life. Her goals have shifted—from professional advancement to simply watching her kids grow up. Whether it's family vacations or bedtime snuggles, she cherishes these moments. Her ultimate aim is to be present for her daughter's high school graduation in 2037. Every step forward, no matter how small, is part of the victory.Want to connect with a Young Adult Survivor Group? Find Kim on Instagram at @YourCancerBestie - http://instagram.com/yourcancerbestieThanks to our Season 19 sponsors, Incyte and Sanofi.https://incyte.com/https://www.sanofi.com/en00:40 – Introduction to Rebecca Heimsoth01:00 – Diagnosis at Age 33 and Initial Symptoms02:07 – Preparing for Transplant and Family Separation04:20 – Emotional Toll and Health Concerns06:20 – Importance of Physical Therapy and Walking06:53 – Balancing Flare-Ups, Appointments, and Parenthood08:20 – Role of Caregivers: Mom and Husband's Support09:43 – Kids' Resilience and Coping with Germ Concerns11:13 – Creative Ways to Explain Cancer to Children13:57 – Impact on Friendships and Social Life16:25 – Finding Online Support Networks and Groups17:43 – Meeting a Fellow Survivor in Person21:35 – Advice for Managing GVHD Symptoms23:16 – Navigating Nutrition with a Busy Family24:40 – Cognitive Health and Chemo Brain Hacks27:52 – Life After Transplant: Gratitude, Travel, and Parenting30:56 – Career Impact and Redefining Success32:23 – Living for the Milestones and Creating New Goals32:51 – Final Reflections and Words of Thanks National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.To participate in the GVHD Mosaic, click here: https://amp.livemosaics.com/gvhd Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of ASTCT Talks, supported by an educational grant from Sanofi US, Dr. Corey Cutler, from Dana-Farber Cancer Institute, and Dr. Guang-Shing Cheng, from the University of Washington and Fred Hutchinson Cancer Center, discuss how to identify and manage non-infectious lung complications following allogeneic transplant. From differentiating infection versus inflammation to managing conditions like organizing pneumonia (OP), this conversation offers practical insights for clinicians.For a deeper dive, explore Dr. Cheng's many publications on pulmonary topics in the Journal of Transplantation and Cellular Therapy. Additionally, read the article “Late-Onset Noninfectious Pulmonary Complications after Hematopoietic Stem Cell Transplantation” by Harris et al. shared in a September 2024 GVHD Supplement collection by the journal.

In this episode of ASTCT Talks, supported by an educational grant from Sanofi US, host Dr. Corey Cutler, MD, from Dana-Farber Cancer Institute, sits down with Dr. Sanjeet Singh Dadwal, MD, chief of infectious diseases at City of Hope, to explore a critical aspect of chronic graft-versus-host disease (GVHD): immune dysfunction and infection risk.The discussion highlights:• How chronic GVHD independently contributes to immune deficits and infection susceptibility.• Infectious risks associated with FDA-approved therapies for chronic GVHD.• Common infections in this population and why vigilance matters.• Practical guidance on prophylaxis strategies, vaccination timing, and navigating real-world challenges like food safety.This episode offers actionable insights for clinicians managing infection prevention and survivorship care in patients with chronic GVHD.Read “Infectious Disease Considerations in Chronic Graft-versus-Host Disease and Transplantation Survivors,” included in the 2024 GVHD Supplement collection published by Transplantation and Cellular Therapy.

Welcome to Marrow Masters season 19 with a focus on chronic GVHD. There are so many exciting advances regarding C-G-V-H-D taking place. We'll be talking with a variety of speakers this season, who will share their experiences, advice, coping mechanisms, updates, and tips to make this rare disease more manageable.We will hear from doctors at the forefront of research and treatment, as well as survivors, caregivers, and advocate-leaders in this space.Season 19 of Marrow Masters will be out on December 18, 2025.Thanks to our Season 19 sponsors, Incyte and Sanofi.https://incyte.com/https://www.sanofi.com/en National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.To participate in the GVHD Mosaic, click here: https://amp.livemosaics.com/gvhd Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In Part 2 of the 2026 pipeline series, host Carolyn Liptak welcomes Dr. Amanda Frick, Senior Clinical Manager, Strategic Clinical Intelligence at Vizient, to explore the advanced therapies pipeline: cell therapies, gene therapies, tissue-engineered products, and combination advanced therapy products. The discussion explores major pipeline trends, six leading products to watch, and the growing innovation expected to shape clinical practice in 2026.   Guest speakers:  Amanda Frick, PharmD, BCPS Senior Clinical Manager, Strategic Clinical Intelligence Spend Management Vizient Host: Carolyn Liptak, MBA, BS Pharm Pharmacy Executive Director Center for Pharmacy Practice Excellence (CPPE) Vizient    Show Notes: [00:05] — Introduction Announcer opens the episode. Host Carolyn Liptak introduces the focus on advanced therapies: cell & gene therapies, tissue-engineered products, and combination products. Guest: Dr. Amanda Frick, Senior Clinical Manager, Strategic Clinical Intelligence at Vizient. [01:07] — Defining Advanced Therapies FDA groups cell and gene therapies within advanced therapies. Total FDA-approved advanced therapies: 46. Amanda monitors 29 drug-like therapies within that group. [02:01] — Pipeline Size and Approval Activity S. pipeline: 264 agents in development. About 10 agents approach FDA decision annually. Actual approvals: 5–7 per year on average. [02:56] — Big-Picture Trends in Cell & Gene Therapy Oncology dominates 40–50% of all CGTs in development. Expanding into autoimmune, neurology, and earlier-phase therapies for diabetes, angina, osteoarthritis. Movement toward allogeneic ("off-the-shelf") therapies Designed to overcome limits of autologous cell manufacturing. Reduces wait time and manufacturing failures. Resurgence of therapeutic vaccines Currently 3 approved (Sipuleucel-T, Talimogene, Papzimeos ). 20+ vaccines in the pipeline, largely targeted to cancer. CE program coming Jan 29. [06:13] — Therapy #1:  Tabelecleucel or Tab-cel (Allogeneic EBV-Specific T-Cell Therapy) First allogeneic T-cell therapy expected in the U.S. For EBV-positive post-transplant lymphoproliferative disorder (PTLD). “Off-the-shelf” and donor-derived. [07:07] — Clinical Need & Outcomes Currentstandard of care: rituximab. After relapse, survival

In this week's episode, Blood editor Dr. Laurie Sehn interviews authors Drs. Lorenzo Falchi and Robert Levy on their latest papers published in Blood Journal. Dr. Falchi discusses his work on an open-label, multicenter phase 1b/2 study evaluating fixed-duration epcoritamab with rituximab and lenalidomide in 108 patients with relapsed or refractory follicular lymphoma. Dr. Levy shares his work on demonstrating that in vivo expansion of Tregs in recipients prior to transplant is possible by activating TNFRSF25 (also known as death receptor 3) in combination with low-dose interleukin-2 in preclinical models. Both papers showed impressive and promising results for the treatment of lymphoma and GVHD.Featured ArticlesFixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular LymphomaPre-transplant targeting of TNFRSF25 and CD25 stimulates recipient Tregs in target tissues ameliorating GVHD post-HSCT

Synopsis: Few biotechs can pull off what Syndax Pharmaceuticals has achieved — two first-in-class oncology drug launches, built entirely through strategic in-licensing and disciplined execution. In this episode, host Alok Tayi sits down with Michael Metzger, Chief Executive Officer of Syndax, to explore how the company identified breakthrough assets, advanced them through development, and successfully commercialized them within a span of just a few years. Metzger unpacks Syndax's distinctive model — leveraging external innovation, rapid clinical validation, and precision in go-to-market strategy — to create measurable patient and shareholder value. From the first menin inhibitor approved in acute leukemia to a novel CSF1R antibody reshaping GVHD and fibrosis care, Syndax's portfolio embodies science that scales. The conversation offers an insider's perspective on risk management, deal-making, data-driven decision-making, and why speed to market has become the new differentiator in biotech. A must-listen for investors, executives, and founders navigating the complexities of growth in a capital-intensive industry. Biography: Michael A. Metzger is a seasoned biopharmaceutical executive with extensive leadership experience in company building, operations, and strategic transactions across the life sciences industry. He currently serves as the Chief Executive Officer of Syndax Pharmaceuticals, a publicly traded oncology company, a role he assumed in 2022. Prior to this, Michael served as President and Chief Operating Officer of Syndax from 2015 and has been a member of the company's Board of Directors since 2019. Previously, Michael held leadership roles at Regado Biosciences, Inc, where he served as President and CEO and guided the company through a successful merger with Tobira Therapeutics. He also served as Executive Vice President and COO at Mersana Therapeutics, Inc., where he oversaw key strategic initiatives in ADC development for oncology. Earlier in his career, Michael held senior roles in business development and M&A at Forest Laboratories, LLC, contributing to its transformation ahead of its acquisition by Allergan plc. He also held leadership positions at Onconova Therapeutics, Inc., and was a Managing Director at MESA Partners, Inc., a healthcare-focused venture capital firm. Michael has served on several public and private company boards, including CTI BioPharma Corp., acquired by SOBI AB in 2023, and continues to be active in guiding innovative biotech organizations. Michael holds a B.A. from George Washington University and a M.B.A. in Finance from the NYU Stern School of Business.

In this episode of ASTCT Talks, Dr. Taha Al-Juhaishi is joined by Dr. Filippo Milano, director of the Cord Blood Transplant Program at Fred Hutch, for a wide-ranging conversation on the evolving role of umbilical cord blood transplantation. From its historical milestones to emerging clinical strategies, Dr. Milano shares insights drawn from decades of research, practice and mentorship. The discussion explores the unique biological advantages of cord blood, including its potent graft-versus-leukemia effect and low incidence of chronic GVHD. Dr. Milano outlines ideal patient profiles, unit selection criteria and conditioning regimens, while addressing challenges like engraftment delays and infection risk. As the field looks ahead, Dr. Milano reflects on theimportance of inclusivity, scientific rigor and mentorship to reengage transplant centers and inspire the next generation of clinicians. Whether as a stand-alone therapy or part of a hybrid platform, cord blood transplantation continues to offer hope for patients with high-risk disease and limited donor options.

In this episode, we sit down with Anastasia Cacavias, a registered nurse and manager of the Blood and Marrow Transplant Leukemia Program at Northside Hospital Cancer Institute in Atlanta. Anastasia walks us through the essential role that caregivers play throughout the transplant journey—from initial diagnosis to long-term recovery. Her perspective comes not only from clinical experience but from deeply personal connections with patients and their support systems.We begin by discussing the broad and intensive responsibilities caregivers take on. These range from medication management, symptom monitoring, transportation, and attending every medical appointment to providing emotional support 24/7. Anastasia explains how caregivers are not just passive companions but active partners in medical care. They're educated thoroughly before the patient begins their conditioning regimen, especially about signs of infection, graft-versus-host disease, and other complications.Once patients return home, the caregiver's role intensifies. They're responsible for maintaining a clean home environment, food preparation, hygiene assistance, and ensuring infection control—such as hand washing, mask-wearing, and visitor limitations. Anastasia offers guidance on how caregivers can prepare, including maintaining good communication, staying organized, and using a detailed education notebook provided by the hospital.Self-care for caregivers is a major focus. Anastasia emphasizes that it's okay to admit feeling overwhelmed. She encourages them to take breaks, get proper rest, eat well, and tap into family or community resources for support. Even small actions, like letting someone else bring the patient to the clinic for a few hours, can be meaningful.We also explore more medical territory—highlighting key patient needs such as hydration, nutrition, and mobility. Physical therapy is introduced before transplant and continued after, with an emphasis on realistic daily movement goals. Proper dental care, both pre- and post-transplant, is essential to avoid complications, with tips like using alcohol-free mouthwash and soft-bristled brushes.We touch on important transplant-related complications such as Graft-versus-Host Disease (GvHD) and Veno-Occlusive Disease (VOD). Anastasia details the signs to watch for, treatment protocols, and the hospital's proactive approach, including assigning dedicated GvHD nurses and maintaining 24/7 communication lines for urgent symptoms.Anastasia closes the conversation with moving stories of caregivers who went above and beyond—reminding us of the emotional strength and love that often fuels this journey. These stories reinforce her message: caregivers are central to healing. Without them, recovery would look very different.Northside Hospital: https://www.northside.com/National Marrow Donor Program (NMDP): https://bethematch.orgThis season is sponsored by Sanofi: https://www.sanofi.com/And Jazz Pharmaceuticals: https://www.jazzpharma.com/ National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.To participate in the GVHD Mosaic, click here: https://amp.livemosaics.com/gvhd Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, we sit down with Lorri Pimentel of Santa Rosa, California, a resilient survivor who shares her deeply personal journey through breast cancer, acute myeloid leukemia (AML), and a life-saving bone marrow transplant. We explore not only the medical milestones but also the practical and emotional realities of navigating treatment and recovery, especially in the context of caregiving during the COVID-19 pandemic.Lorri opens by walking us through her diagnosis timeline: first with DCIS breast cancer in 2016, followed by an AML diagnosis in 2019. She underwent intense chemotherapy and, after a relapse, received a stem cell transplant in March 2021. Her story is not only one of medical complexity but also of personal upheaval—she was in the middle of a divorce and raising three children, with limited family caregiving options. Her caregivers were her friends and former work colleagues, who rotated week by week to support her recovery.We dive into Lorri's insights and hard-earned lessons about caregiving and post-transplant life. She stresses the importance of flexibility in caregiver scheduling, being prepared for early hospital discharge, and having a list of essential medical contacts readily available. She advises caregivers to undergo thorough training, keep detailed records for outpatient visits, and maintain strict medication management practices.Lorri doesn't shy away from sharing her missteps. She discusses her experience with Graft-versus-Host Disease (GvHD), the dangers of sun exposure, and complications like mucositis and insomnia. Her tips—like using a water pick, prescription mouthwash, fluoride toothpaste, and avoiding self-medicating with cannabis—are based on lived experience. She also shares less obvious insights, such as the need for UV-protective clothing, avoiding rice leftovers, and managing dry eyes with serum-based drops not yet FDA-approved.Transportation and social isolation were also major themes. Lorri emphasizes the importance of arranging reliable rides to appointments and finding indoor outlets for creativity and community. She found healing in watercolor art, music, yoga, and support groups. Her volunteer work with LLS, now Blood Cancer United, and NMDP reflects her dedication to mentoring others on the same path.We wrap up by discussing Lorri's present-day life. Now more than four years post-transplant, she's active, creative, and grounded in gratitude. Her final message is one of hope and purpose: bone marrow transplant recovery is slow, but it's life-changing, and each day is a gift worth sharing.This season is sponsored by Sanofi: https://www.sanofi.com/And Jazz Pharmaceuticals: https://www.jazzpharma.com/ National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.To participate in the GVHD Mosaic, click here: https://amp.livemosaics.com/gvhd Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Today we sit down with Henry Ford Health Michigan's Hina Desai, an oncology certified social worker with decades of experience, to share her best caregiving tips for those supporting transplant patients. Hina explains that patience, physical stamina, problem-solving, adaptability, and emotional intelligence are essential caregiver skills. We talk about the many roles a caregiver plays — from transportation and medication management to wound care, infection prevention, meal preparation, and emotional support. Staying connected to the healthcare team and keeping friends and family informed are key.We highlight the value of resources like the Leukemia & Lymphoma Society's, now Blood Cancer United's, free nutritional consultations. Hina stresses the importance of understanding the Family Medical Leave Act, planning for potential income loss, and connecting with social workers to access financial help from foundations such as LLS, PAN Foundation, Cancer Care, Angels of Hope, New Day Family Foundation, and NMDP.Hina advises enlisting a support network early. Dividing tasks like grocery shopping, meal prep, transportation, and pharmacy runs helps prevent burnout. She reminds us that transplant caregiving is a marathon — caregivers must look after their physical, emotional, financial, and spiritual wellbeing. This includes setting boundaries, filtering advice, staying flexible, and preparing for setbacks such as relapse or unexpected hospital stays.We discuss unique considerations for CAR T, allogeneic, and autologous transplants. CAR T caregivers should watch for neurological changes. Allogeneic caregivers may handle tasks like IV magnesium infusions and monitor for graft-versus-host disease (GVHD) or veno-occlusive disease (VOD).Caregiving can change relationship dynamics, sometimes causing role reversal. Good communication helps maintain mutual respect. Self-care remains vital: nutritious eating, exercise, spiritual practices, adequate sleep, and support groups can all help sustain the caregiver's energy and emotional health.Hina and Peggy share heartwarming stories of caregivers going above and beyond, from offering a shower to a hospital-bound spouse, to creatively negotiating with doctors so a patient could return to gardening safely. We reflect on the importance of kindness toward oneself, seeking help when needed, and recognizing that caregiving doesn't have to be perfect to be deeply meaningful.  We also highlight three husbands who have stepped up as caregivers to their wives.We close with gratitude for caregivers and the countless ways they support recovery, comfort, and hope for transplant patients.Season 18 of the Marrow Masters podcast is sponsored by Sanofi and Jazz Pharmaceuticals.This season is sponsored by Sanofi: https://www.sanofi.com/And Jazz Pharmaceuticals: https://www.jazzpharma.com/Resources:Leukemia & Lymphoma Society (LLS) is now Blood Cancer United: https://bloodcancerunited.org/PAN Foundation: https://www.panfoundation.orgCancer Care: https://www.cancercare.orgAngels of Hope: https://angelsofhope.orgNew Day Foundation for Families: https://www.foundationforfamilies.orgNational Marrow Donor Program (NMDP): https://bethematch.orgBMT InfoNet: https://www.bmtinfonet.org National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.To participate in the GVHD Mosaic, click here: https://amp.livemosaics.com/gvhd Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of ASTCT Talks, Dr. Corey Cutler is joined by psychiatrist and physician-scientist Dr. Hermioni Amonoo to explore the psychological complexities faced by patients undergoing stem cell transplantation and living with chronic GVHD. Drawing from her research and clinical experience, Dr. Amonoo introduces a biobehavioral framework that integrates biological, psychological and social factors.This episode offers practical insights and compassionate strategies for improving psychological well-being in transplant patients, highlighting the importance of interdisciplinary care.

In this week's episode we'll learn about targeting NPM1 in acute myeloid leukemia. Researchers report the first clinical evidence of a menin inhibitor inducing complete remissions in AML with a NPM1 mutation. This validates NPM1 as a new therapeutic target in AML, alongside FLT3, IDH1/2, and KMT2A. Also on the podcast: targeting CD137 to prevent graft-versus-host disease. In nonhuman primates, a single dose of a CD137 antibody-drug conjugate provided long-term protection, with one important caveat: the potential for viral reactivation.Featured Articles: Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 studyA single dose of a CD137 antibody–drug conjugate protects rhesus macaque allogeneic HCT recipients against acute GVHD

To już ostatni odcinek podcastu o mojej ostrej białaczce szpikowej. Opowiadam w nim o najważniejszym, ale też najtrudniejszym okresie mojego leczenia. Od od przygotowań, przez przeszczep komórek macierzystych od dawczyni ze Szwajcarii, aż po pół roku po. O wszystkich komplikacjach i powikłaniach. Zamykam nim temat choroby. ☻ Postaw mi wirtualną kawę - https://buycoffee.to/u-janoszuk☻ Mój profil na Instagramie - https://www.instagram.com/u_janoszuk/☻ Zapisz się na newsletter "Refleksy" - https://u-janoszuk.pl/newsletter-refleksy/

In this episode of ASTCT Talks, Dr. Corey Cutler sits down with Dr. Anna Barata to discuss the critical role of physician-patient communication in GVHD and stem cell transplantation. Together, they unpack the complex emotional and psychological landscape facing transplant survivors and the communication barriers that often go unspoken. Dr. Barata shares insights into the challenges faced by both patients and providers, ranging from unspoken anxiety and cognitive dysfunction to hesitations around discussing complementary therapies. This episode offers a look at how better communication can transform the transplant experience, making space for shared decision-making, emotional support and truly patient-centered care. 

In the next installment of ASTCT's Titans of Transplant series, Dr. Shernan Holtan sits down with Dr. Daniel Weisdorf—renowned leader, mentor and pioneer in cellular therapy and transplantation—for a reflective and engaging conversation on the evolution of the field. From the early days of sibling-only donors and bone marrow harvests to today's innovations in GVHD prophylaxis and cord blood transplantation, Dr. Weisdorf shares personal anecdotes, pivotal clinical insights and lessons in mentorship, writing and research. Together, they explore the milestones, challenges and future directions in transplant and cellular therapy—offering a powerful perspective on what it means to make a lasting impact in patient care and scientific progress.

In this week's episode, we' ll learn about how TET3 has a key role in GVHD. In mice, a deficiency of Tet3 in donor T cells inhibited pathogenic immunoglobulin class switching and suppressed lung fibrosis. Accordingly, TET3 may be a new therapeutic target in chronic GVHD. After that: rilzabrutinib, a BTK inhibitor for ITP. In a randomized, placebo-controlled trial, treatment produced rapid and durable platelet responses, with acceptable safety, in adults with immune thrombocytopenia who had failed multiple previous therapies. Finally: exploring pre-TCR surface expression patterns in T-cell ALL. Co-inhibition of the interleukin-7 receptor and pre-T cell receptor pathways may play a therapeutic role for a subset of T-lymphoblastic leukemias.Featured Articles: Deficiency of T follicular helper cell Tet3 DNA demethylation inhibits pathogenic IgG2c class switching and chronic GVHDSafety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 studySurface pTα expression predicts LCK activation and preclinical synergy of LCK and JAK coinhibition in adult T-ALL

In this episode of ASTCT Talks, Dr. Shernan Holtan welcomes Andrew Lin, Manager of Clinical Pharmacy Services of Adult BMT and CTS at Memorial Sloan Kettering Cancer Center, to discuss the evolving role of tacrolimus levels in GVHD prophylaxis within the post-transplant cyclophosphamide (PTCy) era. They explore findings from a recent retrospective study examining whether higher tacrolimus levels offer added protection against GVHD, what this means for toxicity and patient outcomes and how these insights are shaping dosing strategies. The conversation also looks ahead to future research areas, including MMF optimization and the potential for simplified, patient-centered prophylaxis regimens.

In this week's episode, we'll learn about stopping myeloma maintenance therapy in the modern era. New research suggests that many patients in remission can discontinue lenalidomide, remaining treatment-free, without jeopardizing disease response. After that: a novel congenital neutropenia syndrome. Mutations in the COPZ1 gene impact myeloid differentiation and development of neutropenia. Researchers describe the mechanisms and propose a treatment strategy for restoring granulopoiesis. Finally, ruxolitinib maintenance therapy after allogeneic transplant. In a phase 2 study, this treatment strategy was associated with low rates of chronic graft-versus-host disease. Investigators say the use of JAK inhibitors in this context warrants further study.Featured Articles: Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myelomaA new severe congenital neutropenia syndrome associated with autosomal recessive COPZ1 mutationsLow rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT

CancerNetwork®, in collaboration with the American Society for Transplantation and Cellular Therapy (ASTCT)®, hosted a Twitter/X Space during the 2025 Tandem Meetings. The live conversation featured Rahul Banerjee, MD, FACP, of Fred Hutchinson Cancer Center, and Shernan Holtan, MD, of Roswell Park Comprehensive Cancer Center. Together, they shared expert commentary on new data in CAR T-cell therapy and hematopoietic cell transplantation.With insights drawn from posters, oral abstracts, and late-breaking presentations, the session unpacked both clinical takeaways and implications for patient care.Highlights included:LBA1 – Ide-cel + lenalidomide maintenance post-transplant in MM patients“This merges two worlds,” said Banerjee. “Not a tandem in the classic sense, but a transplant followed by CAR T.”[Garfall et al., Abstract LBA-1]Abstract 50 – Real-world CAR T use in early relapsed/refractory LBCLHoltan noted, “In this cohort, no statistical survival difference was seen between second- and third-line therapy, though the curves suggest a trend.”[Rojek et al., Abstract 50]Poster 340 – CAR T targeting CD83 in breast cancerBanerjee speculated on future innovations: “If we could deliver these locally, without systemic effects, that would be a game changer.”[Betts et al., Poster 340]Poster 317 – IEC-colitis in cilta-cel-treated patientsBanerjee reflected, “We assumed steroids would help, like with GVHD. But outcomes didn't align.”[Chang Lim et al., Poster 317]Poster 572 – Driving restrictions post-CAR TBanerjee advocated for updated policy: “Patients often can't regain full independence until driving is restored—this restriction lacks strong evidence.”[Banerjee et al., Poster 572]Presentation 58 – Physical function tests to predict ICANS and mortality“These simple tools helped flag patients unlikely to benefit from CAR T,” said Holtan. “This could refine patient selection.”[Herr et al., Presentation 58]Poster 618 – HCT outcomes for MDS patients by age groupHoltan expressed optimism: “We need conditioning regimens that are effective yet gentler—especially for older patients.”[Duarte et al., Poster 618]Presentation 39 – Immune suppression trends post-HCT (18,000+ patients)Looking ahead, Holtan predicted a shift in GVHD care: “In 10 years, steroids may no longer be our go-to.”[Pidala et al., Presentation 39]Poster 516 – Patient experiences with chronic GVHD via social media listeningHoltan emphasized the human element: “We must prioritize mental health, community support, and advocacy alongside clinical treatment.”[Cowden et al., Poster 516]The discussion emphasized not only the clinical relevance of each study but also broader themes—improving quality of life, adjusting standards of care based on real-world findings, and advancing innovation through thoughtful, patient-centered research.References:Garfall AL, et al. Abstract LBA-1. Tandem 2025.Rojek AE, et al. Abstract 50. Tandem 2025.Betts BC, et al. Poster 340. Tandem 2025.Chang Lim KJ, et al. Poster 317. Tandem 2025.Banerjee R, et al. Poster 572. Tandem 2025.Herr M, et al. Presentation 58. Tandem 2025.Duarte FB, et al. Poster 618. Tandem 2025.Pidala J, et al. Presentation 39. Tandem 2025.Cowden M, et al. Poster 516. Tandem 2025.

Welcome to the fourth episode of ASTCT Talks' exclusive 8-part series, supported by an educational grant from Sanofi US. In this episode, former ASTCT President Dr. Corey Cutler sits down with Dr. Connie R. Shi from the Cutaneous Oncology Program at Dana-Farber Cancer Institute. They discuss Dr. Shi's recent article, Cutaneous Chronic Graft-Versus-Host Disease: Clinical Manifestations, Diagnosis, Management, and Supportive Care.Tune in as they explore the complexities of cutaneous GVHD, including acute and chronic presentations, diagnostic challenges and skin-directed treatment strategies such as topical steroids and phototherapy. They also cover key considerations for recognizing and diagnosing cutaneous GVHD in patients of all skin tones and managing long-term complications like skin cancer risk.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/XRT865. CME/NCPD credit will be available until April 25, 2026.The Good, the Bad, and the GVHD: Leveraging Modern Therapeutics to Improve Post-Transplant Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Incyte Corporation, Mallinckrodt Pharmaceuticals, and Mesoblast Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/XRT865. CME/NCPD credit will be available until April 25, 2026.The Good, the Bad, and the GVHD: Leveraging Modern Therapeutics to Improve Post-Transplant Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Incyte Corporation, Mallinckrodt Pharmaceuticals, and Mesoblast Inc.Disclosure information is available at the beginning of the video presentation.

In today's episode, we'll discuss time-limited triplet therapy in relapsed or refractory CLL. Zanubrutinib, venetoclax and obinutuzumab induced deep remissions, and was well tolerated, even in very high-risk patients, and those with prior exposure to targeted therapies. After that: researchers chronicle the development of a patient-reported outcome measure for sclerosis associated with chronic GVHD—graft-versus-host disease. The new symptom scale—currently undergoing validation studies—may provide valuable information regarding severity, functional impact, and response to therapy. Finally, a study of changes in population dynamic rates that underlie inflammation-associated myeloid bias. The work demonstrates the use of mathematical models to deliver critical biological insights and uncover underlying mechanisms.Featured Articles:MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trialDevelopment of the Lee Symptom Scale–Skin Sclerosis for chronic GVHD–associated sclerosisPopulation dynamics modeling reveals that myeloid bias involves both HSC differentiation and progenitor proliferation biases

Dr. Brandon K.K. Fields speaks with Dr. Jennifer Holter-Chakrabarty about her groundbreaking research on fluorine-18 fluorothymidine (FLT) PET in the imaging of gastrointestinal graft-versus-host disease (GVHD) after allogeneic stem cell transplantation. Together, they explore a potential future role for FLT-PET in detection of early and/or subclinical GVHD, which may serve to guide future treatment strategies for transplant patients in years to come. 18F-FLT PET and Blood-based Biomarkers for IdentifyingGastrointestinal Graft versus Host Disease after Allogeneic CellTransplantation. Holter-Chakrabarty and McNally et al. Radiology: Imaging Cancer 2025; 7(1):e240096. 

A stem cell transplant for blood cancer is just the beginning – what may come next for the patient can… The post Beyond the Transplant: Navigating Graft-vs-Host Disease (GVHD) first appeared on The Bloodline with LLS.

In today's episode, we welcome back Dr. Amar Kelkar for part 2 of our two-part discussion on allogeneic transplant. In this episode, we build on our prior discussion regarding transplant, this time focusing on transplant for the treatment of AML. Episode contents: - What are the different conditioning regimens available? - How do we decide which regimen is optimal for our patients? - What is the role of MRD testing? - What is the role of maintenance therapy post-transplant? - What are treatment options for GVHD? - A discussion on racial disparities in transplant ****Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast